GLP-1 era / fat loss
Cagrilintide Dosage: The Amylin Drug to Watch
An amylin-based weight-loss drug with solid phase 2 data, still investigational.
The quick version
- A long-acting amylin drug for weight loss, still investigational.
- Drove 6 to 10.8 percent weight loss over 26 weeks in phase 2.
- The combination with semaglutide is the bigger story.
What it is
Cagrilintide is a long-acting amylin-based drug for weight loss. Amylin is a hormone that helps you feel full. It is often studied next to or combined with semaglutide.
What the research shows
The phase 2 data is solid. In a 706-person trial, weekly cagrilintide drove 6 to 10.8 percent weight loss over 26 weeks, beating placebo at 3 percent, and the top dose edged out an older drug, liraglutide (Lancet, 2021). It is still investigational and not approved on its own. The combo with semaglutide is the bigger story in trials.
What it felt like
I have not run cagrilintide. It is largely a trial-stage drug, so I am reporting the data rather than a personal cycle. I am watching the semaglutide combo closely.
Dosing reality
Trials tested weekly doses from 0.3 up to 4.5 mg, climbing slowly like other injectables in this class. Since it is unapproved, those are study doses, not a label.
The one mistake to avoid
The mistake is treating cagrilintide like a finished product you can dose confidently. The strong numbers came from a controlled trial, not a settled protocol.
Bottom line
Cagrilintide has real phase 2 data and a bright combo future, but it is still investigational. Promising, not yet proven for solo use.
Reminder: I am not a doctor and this is not medical advice. It is my own notes and reading of the research. Peptides sit in a legal grey area, research-grade is a real category, and it is on you to verify your own compliance. Talk to a qualified professional before you start anything, especially if you take other medication.